(Total Views: 634)
Posted On: 03/29/2019 4:29:51 PM
Post# of 30066
Amarantus Provides 2019 Roadmap
JANUARY 7, 2019
"Further updates will be provided later in the first quarter of 2019."
https://www.amarantus.com/news/press-releases...19-roadmap
Todos Medical Raises $1,350,500 In Funding and Finalizes Joint Venture Agreement with Amarantus Bioscience
FEBRUARY 28, 2019
MANF Therapeutics Receives Notices of Allowance Covering MANF Use as Treatment for Parkinson's in Europe and Diabetes in Japan
JANUARY 17, 2019
MANF Therapeutics Receives Notice of Allowance from US Patent & Trademark Office Covering the Use of MANF or CDNF as a Treatment for Glaucoma, Macular Degeneration and Retinitis Pigmentosa
JANUARY 15, 2019
Amarantus Announces Commercialization Partnership With IDEA Pharma for Subsidiaries
JANUARY 11, 2019
Aloha
JANUARY 7, 2019
"Further updates will be provided later in the first quarter of 2019."
https://www.amarantus.com/news/press-releases...19-roadmap
Todos Medical Raises $1,350,500 In Funding and Finalizes Joint Venture Agreement with Amarantus Bioscience
FEBRUARY 28, 2019
MANF Therapeutics Receives Notices of Allowance Covering MANF Use as Treatment for Parkinson's in Europe and Diabetes in Japan
JANUARY 17, 2019
MANF Therapeutics Receives Notice of Allowance from US Patent & Trademark Office Covering the Use of MANF or CDNF as a Treatment for Glaucoma, Macular Degeneration and Retinitis Pigmentosa
JANUARY 15, 2019
Amarantus Announces Commercialization Partnership With IDEA Pharma for Subsidiaries
JANUARY 11, 2019
Aloha
(0)
(0)
